EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY 4.0

Effect of Sodium−Glucose Co‐Transporter‐2 Inhibitor on Estimated Plasma Volume in a Patient With Heart Failure With Reduced Ejection Fraction and a Patient With Heart Failure With Preserved Ejection Fraction

Andreasová Taťána, Málek Filip

Clinical Cardiology · 2024

DOI: 10.1002/clc.24303 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Clinical Cardiology, 2024. Verfasst von Andreasová Taťána und 1 weiteren Autor:innen. Beteiligte Einrichtung: Third Faculty of Medicine, Charles University, Prague, Czech Republic. Hauptthemen laut MEDLINE: Sodium-Glucose Transporter 2 Inhibitors, Heart Failure, Stroke Volume, Plasma Volume. Die Arbeit nennt 16 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Institutional Grant MH CZ-DRO (Na Homolce Hospital-NNH), 00023884.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The increased diuresis after sodium−glucose cotransporter 2 inhibitor (SGLT2i) was associated with a reduction of the estimated plasma volume (ePV) in type 2 diabetic patients. Hypothesis We hypothesized that the early effect of SGLT2i on ePV may be monitored by the change of biomarkers of hemoconcentration. Patients and Methods We analyzed the early‐ and long‐term effect of SGLT2i empagliflozin on the ePV as assessed by biomarkers of hemoconcentration in a nondiabetic patient with heart failure and reduced ejection fraction (HFrEF) and a nondiabetic patient with heart failure and preserved ejection fraction (HFpEF). The ePV was calculated from hemoglobin and hematocrit levels by Duarte formula and ePV change was calculated by Strauss formula.

Results

The ePV change was −22.56% between baseline and 1 month, and −37.60% between baseline and 12 months follow‐up in a patient with HFrEF, and −6.18% and −16.40% in a patient with HFpEF, respectively.

Conclusion

The early effect of SGLT2i on ePV in patients with heart failure may be monitored by biomarkers of hemoconcentration.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Sodium-Glucose Transporter 2 InhibitorsHeart FailureStroke VolumePlasma VolumeHumansMaleBenzhydryl CompoundsAgedBiomarkersVentricular Function, LeftGlucosidesDiabetes Mellitus, Type 2FemaleTreatment OutcomeMiddle AgedTime Factors

Stichwörter der Autor:innen

biomarkerheart failurehemoconcentrationplasma volumesodium−glucose co‐transporter‐2 inhibitor

Substanzen

Sodium-Glucose Transporter 2 InhibitorsBenzhydryl CompoundsempagliflozinBiomarkersGlucosides

Autor:innen und Institutionen

  • Third Faculty of Medicine, Charles University, Prague, Czech Republic.
  • Center of Nuclear Medicine, Faculty Hospital Bulovka, Prague, Czech Republic.
  • Na Homolce Hospital, Prague, Czech Republic.

Förderung

  • Institutional Grant MH CZ-DRO (Na Homolce Hospital-NNH), 00023884

Zitieren

APA

Taťána, A., & Filip, M. (2024). Effect of Sodium−Glucose Co‐Transporter‐2 Inhibitor on Estimated Plasma Volume in a Patient With Heart Failure With Reduced Ejection Fraction and a Patient With Heart Failure With Preserved Ejection Fraction. Clinical Cardiology. https://doi.org/10.1002/clc.24303

Vancouver

Taťána A, Filip M. Effect of Sodium−Glucose Co‐Transporter‐2 Inhibitor on Estimated Plasma Volume in a Patient With Heart Failure With Reduced Ejection Fraction and a Patient With Heart Failure With Preserved Ejection Fraction. Clinical Cardiology. 2024. doi:10.1002/clc.24303

BibTeX
@article{Tana2024,
  author = {Taťána, Andreasová and Filip, Málek},
  title = {Effect of Sodium−Glucose Co‐Transporter‐2 Inhibitor on Estimated Plasma Volume in a Patient With Heart Failure With Reduced Ejection Fraction and a Patient With Heart Failure With Preserved Ejection Fraction},
  journal = {Clinical Cardiology},
  year = {2024},
  doi = {10.1002/clc.24303}
}
Kostenlos starten →